Alcohol Use Disorder
Conditions
Brief summary
This study aims to detect how the Web-based program SALIENCE affects patients with alcohol-use Disorder in terms of craving, cognitive functions and risk of relapse.
Detailed description
In the web-based program SALIENCE (Stop Alcohol In Everyday life - New Choices and Evaluations) the patient has to make decisions for non-alcoholic and against alcoholic drinks. Therefore there are several scenarios, which are supposed to let the patient integrate these choices into a realistic, everyday life, setting and help the patient to maintain abstinence in upcoming high risk situations. It has been developed as an add-on therapy to increase the overall outcome. Participating patients with alcohol-use disorder are to receive an initial screening including questionnaires and neuropsychological tests. Then the patients receive three training sessions with SALIENCE each week. After three weeks there is another examination. After these three weeks, there is a 90 day period in which there are online follow-ups every two weeks to assess the craving and relapse of the participants. After the 90 day period there is a third examination analog to the first and the second one. For the first 25 subjects, the follow-up and T3 will be omitted; for this collective, an interim evaluation will be performed after T2 as a pilot study, followed by optimization of the protocol if necessary. The first 25 subjects will all receive SALIENCE; a comparison with standard therapy is not planned for this collective. There will be 2 weeks between T1 and T2 in the pilot study.
Interventions
BEHAVIORALSALIENCE
3 computer-based training sessions with program SALIENCE per week over 3 weeks (see study description)
BEHAVIORALTAU
treatment as usual, , i.e. medically supervised detoxification treatment (i.e. medical management of withdrawal symptoms, associated physical discomfort and any co-existing disorders, etc.) as well as health education and supportive therapy sessions.
Sponsors
Central Institute of Mental Health, Mannheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
one group receives add-on- intervention SALIENCE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* age between 18 and 65 * alcohol use disorder (DSM-5) * inpatient or part inpatient treatment * alcohol abstinence for at least 72 hours and maximum for three weeks * normal or correctable eyesight * Sufficient ability to communicate with the investigators, to answer questions in oral and written form * Fully Informed Consent * Written Informed Consent
Exclusion criteria
* Withdrawal of the declaration of consent * severe internistic, neurological or psychiatric comorbidities * severe withdrawal symptoms (CIWA-R \> 7) * alcohol-intoxication (\> 0 ‰) * Pharmacotherapy with psychoactive substances within the last 14 days (except Clomethiazole or Benzodiazepines within the alcohol withdrawal treatment; treatment with these medications has to be completed within last 3 days) * Axis 1 disorder according to ICD-10 and DSM 5 (except tobacco use disorder and specific phobia within the last 12 months)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in alcohol craving | directly before and after each SALIENCE session (3 SALIENCE sessions per week over 3 weeks) | Visual Analogue Scale |
| Change in attentional bias | directly before and after each SALIENCE session (3 SALIENCE sessions per week over 3 weeks) | Dotprobe-Task (MacLeod, Mathews, & Tata, 1986) |
| Change in alcohol interference | directly before and after each SALIENCE session (3 SALIENCE sessions per week over 3 weeks) | Alcohol Stroop Test (Brand, Leichsenring-Driessen, Beblo, Kremer, & Driessen, 2009) |
| Change in approach-avoidance tendencies | directly before and after each SALIENCE session (3 SALIENCE sessions per week over 3 weeks) | Approach Avoidance Task (AAT) (R. W. Wiers et al., 2009) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relapse | 90 days after study inclusion | time to first severe relapse |
Countries
Germany
Outcome results
None listed